HOME > Registration > R+T Meeting
Agenda and table host information
Part 1: Bio innovative technologies and measures for future collaboration
Table No. Logo Agenda and table host information Introductory material
1-1.

Analytic methods and solutions for a strategic development of bio pharmaceutical goods (therapeutic protein etc.) : USP Biological Standards

Fouad Atouf, USP VP
1-2.

The Korean cell treatment development status and its future leveraging iPSc (induced pluripotent stem cell)

Ju, Ji Hyeon, Professor with the Catholic University of Korea Seoul St.Mary's Hospital
1-3.

The innovative technology of bio-pharmaceutical goods development ventures in North America and the Korean bio-pharma market attractions

PlantForm Corporation
1-4.

Immune booster platform technologies and vaccine self-sufficiency

Cho, Gwan Ku, CEO of Quratis
1-5.

Development of Platform for Process Automation in Cell-based Therapy

Jungmin Cho, Director of Curiosis Inc.
Luncheon : Global Pharma Market Entry Strategy through Collaboration between Large and small bio companies / 12:00 – 14:00
Time Logo Agenda and table host information Introductory material
12:10-12:15

Welcome Remark

James Yoon (VP, Samsung BioLogics)
12:15-12:30

Faster & Better, Your Success to IND and BLA

Eun Young Yang (Samsung BioLogics)
12:30-12:50

유틸렉스의 항암 T세포 치료제와 항체 치료제의 개발 전략

Kwon Byoung S., CEO of Eutilex
12:50-13:10

Value Creation through Strategic Partnership with CDMO

Nam Su-Youn, CEO of GI Inovation
13:10-13:30

TBD

Song Yun Jeong, CEO of ImmuneOncia
13:30-13:55

Closing Remark, Free Networking/Wrap-up

Part 2: Bio Open Innovation
Table No. Logo Agenda and table host information Introductory material
2-1.

Global partnership for open innovation

Hunwoo Shin, SVP at MSD
2-2.

Challenge for the first local antibody-drug for cancer therapy

Yoo Jin San, CEO of Pharmabcine
2-3.

Human micro-biome technology platform

Prof. Ko, Gwang Pyo, CEO of Kobiolab
2-4.

1011 diversity, cDNA library and identifying candidate substance

Park, Young Woo, CEO of Y biologics
2-5.

Stem cell treatment development status and joint research

Rhee, Byung Gun, CEO of SCM Lifescience
2-6.

Clinical development trend by using nano bio-technology

Kyung Hae Lee, Director of Bio-graphene

* Above programs and schedule are subject to change.